Diabetes Drug R&D Services
x
- Home
- Diabetes Models
- In Vivo Models of Diabetes Mellitus
- In Vitro Models of Diabetes Mellitus
- Diabetes Drug R&D Services
- Therapeutic Areas
- Virtual Booth
- Company
Diabetes Drug R&D Services
Accelerate your antidiabetic drug development pipeline with our end-to-end preclinical research services, from discovery to preclinical development and biomarker identification.
Make an InquiryThe diabetes therapeutics market is rapidly evolving, with new targets, mechanisms, and technologies emerging to address this global health challenge.
Despite significant advances, diabetes remains a major unmet medical need with increasing global prevalence. The pipeline is shifting toward novel mechanisms, personalized therapies, and addressing comorbidities and complications.
Growing Pipeline Diversity
Shift from traditional small molecules to biologics, cell therapies, and gene therapies
Focus on Complications
Increasing emphasis on drugs that address diabetic nephropathy, retinopathy, and neuropathy
Personalized Approaches
Therapies tailored to specific patient populations and disease subtypes
Translational Gap
Difficulty translating preclinical findings to clinical success, with high failure rates in late-stage trials.
Disease Complexity
Heterogeneous nature of diabetes and comorbidities complicates drug development and patient stratification.
Long Development Timelines
Extended time required to demonstrate long-term efficacy and safety in chronic disease management.
Regulatory Challenges
Evolving regulatory requirements for demonstrating cardiovascular and renal safety.
Biomarker Identification
Lack of validated biomarkers for early efficacy assessment and patient stratification.
High Development Costs
Expensive late-stage trials and high failure rates increase the cost of successful drug development.
Our discovery services cover the entire preclinical pipeline across target identification and lead optimization, driven by a focus on novel mechanisms and enhanced therapeutic value.
Our preclinical development services comprehensively evaluate the efficacy, safety, and pharmacokinetics of your drug candidate to meet the regulatory requirements for IND submission.
Efficacy Testingy
Dose-response studies, glycemic control assessment, and long-term efficacy in validated animal models.
Safety Pharmacologys
Cardiovascular, respiratory, and central nervous system safety assessments per ICH guidelines.
Toxicology Studies
Acute, subchronic, and chronic toxicity evaluations to determine safety margins and potential adverse effects.
Pharmacokinetic Profiling
Absorption, distribution, metabolism, and excretion studies across species to support clinical dosing.
Preclinical Efficacy Assessment of Antidiabetic Drugs
Systematic testing is performed in in vitro and in vivo diabetes models, assessing core metrics: glycemic control, insulin sensitivity, and β-cell function.
ADME & DMPK Studies for Antidiabetic Drug
Comprehensive profiling of core ADME properties and in vivo PK parameters to de-risk candidate selection.
Preclinical Safety Assessment of Antidiabetic Drugs
Comprehensive safety profiling including toxicity, adverse effect monitoring, and drug-drug interaction studies.
Our biomarker services enable the identification, validation, and application of diabetes-specific biomarkers—supporting early diagnosis, treatment response monitoring, and clinical trial enrichment.
| Biomarker Type | Key Biomarkers | Applications |
| Protein Biomarkers | Insulin, C-peptide, HbA1c, adiponectin, resistin, TNF-α, IL-6 | Disease diagnosis, treatment response, complication risk |
| RNA Biomarkers | miR-126, miR-146a, miR-223, PPARG, IRS1, GLUT4 | Pathophysiology research, patient stratification |
| Metabolite Biomarkers | Glucose, lactate, pyruvate, branched-chain amino acids, fatty acids | Glycemic control monitoring, metabolic profiling |
Biomarkers Development Services of Vascular Function in Diabetes
Identification of biomarkers for diabetic vasculopathy, endothelial dysfunction, and cardiovascular complications.
Learn MoreGlucose-Related Biomarker Development Services
Validation of biomarkers for glucose metabolism, insulin secretion, and glycemic control.
Learn MoreInsulin Resistance-Related Biomarker Development Services
Biomarkers for skeletal muscle, hepatic, and adipose tissue insulin resistance.
Learn MoreMolecular Biomarker Development Services for Diabetes
Genomic, transcriptomic, and epigenomic biomarkers for personalized medicine.
Learn MoreTissue Biomarker Development Services for Diabetes
Tissue-specific biomarkers for pancreatic, hepatic, and adipose tissue function.
Learn MoreBiospecimen Collection and Analysis Services for Diabetes Research
Specialized services for collection, processing, storage, and analysis of diabetes-related biospecimens.
Learn MoreOur integrated research platforms combine cutting-edge technology with specialized expertise to deliver high-quality data for your diabetes drug development program.
High-Throughput Screening Platform
Automated screening of 100,000+ compounds monthly using 384-well formats, with integrated detection systems for glucose uptake, insulin secretion, and cell viability.
Metabolomics & Lipidomics Platform
Advanced mass spectrometry (LC-MS/MS, GC-MS) for comprehensive metabolic profiling, with capacity to analyze 500+ metabolites and lipids in biological samples.
Imaging & Phenotyping Platform
Integrated imaging (DEXA, micro-CT, fluorescence) for quantitative assessment of body composition, pancreatic function, and diabetic complications.
Histopathology Platform
Automated tissue processing and diabetes-specific multimodal imaging enable quantitative assessment of pancreatic islet morphology, β-cell mass, and target organ (kidney/liver) pathological changes for drug efficacy evaluation.
Molecular Biology Platform
Genomic and transcriptomic analysis using next-generation sequencing (NGS), qPCR arrays, and RNA-seq to identify diabetes-related molecular pathways.
In Vivo Physiology Platform
Telemetry and metabolic cages for continuous monitoring of glucose levels, blood pressure, activity, and food/water intake in animal models.
Valid Animal Models
Access a comprehensive panel of validated animal models for type 1 and type 2 diabetes that ensure translatable results.
Advanced Analytics
State-of-the-art analytical platforms for metabolic profiling, biomarker discovery, and high-throughput screening.
Regulatory Compliance
All studies are performed in full regulatory compliance to support the preparation of your global submission.
Expert Scientific Team
Ph.D.-level scientists with deep expertise in diabetes pathophysiology and drug development.
Based on your diabetes drug development needs, we' ve curated these high-impact services to de-risk your program and accelerate time to market.
Find answers to common questions about our diabetes drug R&D services.
What animal models do you offer for diabetes research?
How long does a typical preclinical efficacy study take?
The duration of preclinical efficacy studies varies depending on the study design, animal model, and specific endpoints. Typically, studies range from 4 to 12 weeks. Our project managers will provide a detailed timeline during the study design phase, and we offer accelerated study options for time-sensitive programs.
Do your biomarker services include validation?
Yes, our biomarker development services include comprehensive validation studies. We follow a rigorous process from discovery through qualification and validation, ensuring that biomarkers meet the required performance characteristics for their intended use. Our team can also assist with assay development and transfer for continued use in your drug development program.
Do you have specialized technical platforms for diabetes drug development?
Yes, we leverage industry-leading platforms: validated diabetic animal models (db/db mice, ZDF rats), high-throughput screening for glucose-lowering agents, GLP-1 receptor agonist characterization, and translational pharmacology tools. Our platforms comply with global regulatory standards for reproducibility and data integrity.
Do you offer specialized services for evaluating diabetes complications?
Yes, we have specialized models and assays for evaluating diabetes complications including nephropathy, retinopathy, neuropathy, and cardiovascular disease. Our services include functional assessments, histological evaluation, and biomarker analysis specific to each complication. We can design studies to evaluate both disease-modifying and symptomatic effects of your therapeutic candidates on diabetes complications.
Our diabetes research experts are ready to help accelerate your drug development program. Fill out the form to get started.
Leave Your Message Here
Our Expertise
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
